AT
The startup operates a proprietary modular platform that develops site-specific antibody-drug conjugation technology to create novel therapeutic molecules targeting oncology. This technology enhances the therapeutic index, enabling biotechnology companies to improve treatment outcomes for cancer patients.
Updated 4 months ago
Funding
$9.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup operates a proprietary modular platform that develops site-specific antibody-drug conjugation technology to create novel therapeutic molecules targeting oncology. This technology enhances the therapeutic index, enabling biotechnology companies to improve treatment outcomes for cancer patients.